Alembic site slapped with FDA warning letter over patient consent concerns

Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has received a harsher reprimand from the U.S. FDA.

Source: FiercePharma